vs
Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and ASTRAZENECA PLC (AZN). Click either name above to swap in a different company.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
AARD vs AZN — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $14.5B |
| Net Profit | $-17.6M | $2.4B |
| Gross Margin | — | 82.9% |
| Operating Margin | — | 24.3% |
| Net Margin | — | 16.9% |
| Revenue YoY | — | 11.7% |
| Net Profit YoY | — | 27.0% |
| EPS (diluted) | $-0.81 | $1.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | $14.5B | ||
| Q1 25 | $0 | — | ||
| Q2 24 | — | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q2 22 | — | $10.8B |
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | — | ||
| Q2 25 | $-14.4M | $2.4B | ||
| Q1 25 | $-9.3M | — | ||
| Q2 24 | — | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q2 22 | — | $360.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 82.9% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q2 22 | — | 72.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 24.3% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q2 22 | — | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 16.9% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q2 22 | — | 3.3% |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | — | ||
| Q2 25 | $-0.66 | $1.57 | ||
| Q1 25 | $-0.71 | — | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q2 22 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.0M | $7.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.6M | $44.8B |
| Total Assets | $117.2M | $112.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $110.0M | — | ||
| Q3 25 | $126.3M | — | ||
| Q2 25 | $141.8M | $7.1B | ||
| Q1 25 | $151.3M | — | ||
| Q2 24 | — | $6.9B | ||
| Q2 23 | — | $5.7B | ||
| Q2 22 | — | $4.8B |
| Q4 25 | $106.6M | — | ||
| Q3 25 | $122.4M | — | ||
| Q2 25 | $136.9M | $44.8B | ||
| Q1 25 | $150.7M | — | ||
| Q2 24 | — | $39.6B | ||
| Q2 23 | — | $37.4B | ||
| Q2 22 | — | $36.0B |
| Q4 25 | $117.2M | — | ||
| Q3 25 | $133.2M | — | ||
| Q2 25 | $147.5M | $112.4B | ||
| Q1 25 | $157.0M | — | ||
| Q2 24 | — | $104.3B | ||
| Q2 23 | — | $96.5B | ||
| Q2 22 | — | $96.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.8M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.8M | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.8M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
